5-hydroxypropafenone has been researched along with nifekalant in 1 studies
| Studies (5-hydroxypropafenone) | Trials (5-hydroxypropafenone) | Recent Studies (post-2010) (5-hydroxypropafenone) | Studies (nifekalant) | Trials (nifekalant) | Recent Studies (post-2010) (nifekalant) |
|---|---|---|---|---|---|
| 59 | 3 | 3 | 12 | 0 | 10 |
| Protein | Taxonomy | 5-hydroxypropafenone (IC50) | nifekalant (IC50) |
|---|---|---|---|
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 10 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 4.6 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 2.75 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Du, LP; Li, MY; Tsai, KC; Xia, L; You, QD | 1 |
1 other study(ies) available for 5-hydroxypropafenone and nifekalant
| Article | Year |
|---|---|
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Models, Biological; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2004 |